Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.

Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M and 5 more

Show all authors

Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y

Hepatology research : the official journal of the Japan Society of Hepatology5 Dec 2016Cited by 68 (Europe PMC)

PMID27917557DOI10.1111/hepr.12837PepBankPUB-27917557

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In Japanese patients with NAFLD and T2DM, dulaglutide was linked to lower body weight than baseline.
In plain wordsIn Japanese patients with NAFLD and T2DM, dulaglutide was linked to lower body weight than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight
Study
n = 15
Comparator
Before treatment
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg weekly · 12 weeksAs given in this study (human).
Source sentences
Summary
Not only body weight and hemoglobin A1c but also transaminase activities were significantly decreased after the 12-week therapy with dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen biopsy-proven NAFLD patients with T2DM refractory to diet intervention who received once weekly dulaglutide 0.75 mg for 12 weeks were retrospectively enrolled after exclusion of two patients by 12 weeks.
Report a problemFND-2791755701
02HumanObservational studyEfficacy outcome
In Japanese patients with NAFLD and T2DM, dulaglutide was linked to lower HbA1c than baseline.
In plain wordsIn Japanese patients with NAFLD and T2DM, dulaglutide was linked to lower HbA1c than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n = 15
Comparator
Before treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg weekly · 12 weeksAs given in this study (human).
Source sentences
Summary
Not only body weight and hemoglobin A1c but also transaminase activities were significantly decreased after the 12-week therapy with dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen biopsy-proven NAFLD patients with T2DM refractory to diet intervention who received once weekly dulaglutide 0.75 mg for 12 weeks were retrospectively enrolled after exclusion of two patients by 12 weeks.
Report a problemFND-2791755702
03HumanObservational studyEfficacy outcome
In Japanese patients with NAFLD and T2DM, dulaglutide was linked to lower transaminase activities than baseline.
In plain wordsIn Japanese patients with NAFLD and T2DM, dulaglutide was linked to lower liver enzyme activities than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTransaminase activities
Study
n = 15
Comparator
Before treatment
Outcome group
Liver fat and liver function · Liver
Studied dose
0.75 mg weekly · 12 weeksAs given in this study (human).
Source sentences
Summary
Not only body weight and hemoglobin A1c but also transaminase activities were significantly decreased after the 12-week therapy with dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen biopsy-proven NAFLD patients with T2DM refractory to diet intervention who received once weekly dulaglutide 0.75 mg for 12 weeks were retrospectively enrolled after exclusion of two patients by 12 weeks.
Report a problemFND-2791755703
04HumanObservational studyEfficacy outcome
In Japanese patients with NAFLD and T2DM, dulaglutide was linked to lower total body fat mass than baseline.
In plain wordsIn Japanese patients with NAFLD and T2DM, dulaglutide was linked to lower total body fat mass than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTotal body fat mass
Study
n = 5
Comparator
Before treatment
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg weekly · 12 weeksAs given in this study (human).
Source sentences
Summary
Total body fat mass and liver stiffness measurement also decreased after the treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
In five patients, transient elastography and body composition were also evaluated before and after the treatment.
Summary · context
Fifteen biopsy-proven NAFLD patients with T2DM refractory to diet intervention who received once weekly dulaglutide 0.75 mg for 12 weeks were retrospectively enrolled after exclusion of two patients by 12 weeks.
Report a problemFND-2791755704
05HumanObservational studyEfficacy outcome
In Japanese patients with NAFLD and T2DM, dulaglutide was linked to lower liver stiffness than baseline.
In plain wordsIn Japanese patients with NAFLD and T2DM, dulaglutide was linked to lower liver stiffness than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseLiver stiffness
Study
n = 5
Comparator
Before treatment
Outcome group
Liver fat and liver function · Liver
Studied dose
0.75 mg weekly · 12 weeksAs given in this study (human).
Source sentences
Summary
Total body fat mass and liver stiffness measurement also decreased after the treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
In five patients, transient elastography and body composition were also evaluated before and after the treatment.
Summary · context
Fifteen biopsy-proven NAFLD patients with T2DM refractory to diet intervention who received once weekly dulaglutide 0.75 mg for 12 weeks were retrospectively enrolled after exclusion of two patients by 12 weeks.
Report a problemFND-2791755705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.